Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway

  • M. Hoff
  • S. Skurtveit
  • H.E. Meyer
  • A. Langhammer
  • A.J. Søgaard
  • U. Syversen
  • E. Skovlund
  • B. Abrahamsen
  • S. Forsmo
  • B. Schei
Original Article

Abstract

Summary

Use of anti-osteoporotic drugs (AODs) was examined in a Norwegian population 50–85 years. Among them with Fracture Risk Assessment Tool (FRAX) score for major osteoporotic fracture ≥ 20, 25% of the women and 17% of the men received AODs. The strongest predictors for AODs were high age in women and use of glucocorticoids among men.

Introduction

To examine the use of anti-osteoporotic drugs (AODs) and to identify predictors for prescriptions.

Methods

Data were obtained from the Nord-Trøndelag Health Study (HUNT3) performed in 2006–2008 and the Norwegian Prescription Database, including 15,075 women and 13,386 men aged 50–85 years. Bone mineral density (BMD) in the femoral neck was measured in a subgroup of 4538 women and 2322 men. High fracture risk was defined as a FRAX score for major osteoporotic fracture (MOF) ≥ 20%; in the subgroup with BMD, high risk was in addition defined as FRAXMOF ≥ 20% or T-score ≤ − 2.5. Hazard ratios (HRs) for predictors of incident use of AODs within 2 years after HUNT3 were estimated by Cox’ proportional hazards model.

Results

Among individuals with FRAX MOF ≥ 20%, 25% of the women and 17% of the men were treated with AODs. Among those with FRAX MOF < 20%, 3% and 1% were treated, respectively. In the subgroup with BMD measurement, 24% of the women and 16% of the men at high risk of fractures were treated, compared to 3 and 1% in women and men not fulfilling the criteria. In women, high age was the strongest predictor for treatment (HR 3.84: 95% confidence interval 2.81–5.24), followed by use of glucocorticoids (GCs) (2.68:1.84–3.89). In men, predictors were use of GCs (5.28: 2.70–10.35) followed by multimorbidity (3.16:1.31–7.63). In the subgroup with BMD, T-score ≤ − 2.5 was the strongest predictor (women 3.98:2.67–5.89; men 13.31:6.17–28.74).

Conclusions

This study suggests an undertreatment of AODs in individuals at high risk of fracture.

Keywords

Osteoporosis Anti-osteoporotic drugs General population studies HUNT 

Notes

Acknowledgements

The Nord-Trøndelag Health Study (The HUNT Study) is in collaboration between HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology NTNU), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health.

Funding information

MH received a postdoctoral fellowship grant from the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU).

Compliance with ethical standards

Conflicts of interests

BA has institutional research contracts with UCB and Novartis with funds paid to the institutions.

US has received research grants from or served as a Principal Investigator in studies conducted by Amgen, Eli Lilly, Novartis, Merck and Wyeth pharmaceuticals.

MH, SS, HM, AD, AJS, AL, ES and BS have no disclosures.

References

  1. 1.
    Singer A, Exuzides A, Spangler L, O’Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan R (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90:53–62CrossRefPubMedGoogle Scholar
  2. 2.
    Cauley JA, Chalhoub D, Kassem AM, Fuleihan Gel H (2014) Geographic and ethnic disparities in osteoporotic fractures. Nat Rev Endocrinol 10:338–351CrossRefPubMedGoogle Scholar
  3. 3.
    Cheng SY, Levy AR, Lefaivre KA, Guy P, Kuramoto L, Sobolev B (2011) Geographic trends in incidence of hip fractures: a comprehensive literature review. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 22:2575–2586CrossRefGoogle Scholar
  4. 4.
    Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C, on behalf of the IOFWGoE, Quality of L (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 23:2239–2256Google Scholar
  5. 5.
    (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. AmJMed 94:646–650Google Scholar
  6. 6.
    (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129Google Scholar
  7. 7.
    Crandall CJ, Newberry SJ, Diamant A, et al. (2012) Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report. Rockville MDGoogle Scholar
  8. 8.
    Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161:711–723CrossRefPubMedGoogle Scholar
  9. 9.
    Hoff M, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U, Abrahamsen B, Schei B (2015) Use of anti-osteoporotic drugs in central Norway after a forearm fracture. Arch Osteoporos 10:235CrossRefPubMedGoogle Scholar
  10. 10.
    Devold HM, Sogaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE (2013) Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int: J established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA 24:1225–1233CrossRefGoogle Scholar
  11. 11.
    Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    (2005) Norwegian guidelines for prevention and treatment of osteoporosis and osteoporotic fracturesGoogle Scholar
  13. 13.
    Black DM, Rosen CJ (2016) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 374:254–262CrossRefPubMedGoogle Scholar
  14. 14.
    Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int: J Established Result Cooperation Between Eur Found Osteoporosis Natl Osteoporos Found USA 25:2359–2381CrossRefGoogle Scholar
  15. 15.
    Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX and its applications to clinical practice. Bone 44:734–743CrossRefPubMedGoogle Scholar
  16. 16.
    Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Papaioannou A, Morin S, Cheung AM, et al. (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ : Can Med Assoc J = J de l'Association medicale canadienne 182:1864–1873, 2010Google Scholar
  18. 18.
    Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int: J Established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA 25:1439–1443CrossRefGoogle Scholar
  19. 19.
    Finnes TE, Syversen U, Bakke Å, Høiberg M, Eriksen EF (2015) National guidelines in endocrinology, osteoporosis. http://www.helsebiblioteket.no/retningslinjer/endokrinologi-veileder/osteoporose-og-paratyroidea/osteoporose
  20. 20.
    (2015) The Norwegian Society for rheumatology: osteoporosis: investigation, treatment and follow-up http://legeforeningen.no/PageFiles/229641/Osteoporose%20%202015.pdf
  21. 21.
    Wastesson JW, Ringback Weitoft G, Parker MG, Johnell K (2013) Educational level and use of osteoporosis drugs in elderly men and women: a Swedish nationwide register-based study. Osteoporos Int: J Established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA 24:433–442CrossRefGoogle Scholar
  22. 22.
    Krokstad S, Langhammer A, Hveem K, Holmen T, Midthjell K, Stene T, Bratberg G, Heggland J, Holmen J (2012) Cohort profile: the HUNT study, Norway. Int J EpidemiolGoogle Scholar
  23. 23.
    Hoff M, Meyer HE, Skurtveit S, Langhammer A, Sogaard AJ, Syversen U, Dhainaut A, Skovlund E, Abrahamsen B, Schei B (2017) Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USAGoogle Scholar
  24. 24.
    The Norwegian Prescription Database. The Norwegian Institute of Public Health. http://www.norpd.no/
  25. 25.
    Furu K (2008) Establishment of the nationwide Norwegian Prescription Database (NorPD)—new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi:129–136Google Scholar
  26. 26.
    (2012) WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Norway: OsloGoogle Scholar
  27. 27.
    (2004, revised 2014) Regulations concerning food supplement in Norway https://lovdata.no/dokument/SF/forskrift/2004-05-20-755Google Scholar
  28. 28.
    Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ (2012) Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf 21:297–304CrossRefPubMedGoogle Scholar
  29. 29.
    Cummings S, Nevitt MC, Browner WS, Stone KL, Fox K, Ensrud K, Cauley JA, Black D, Vogt T (1995) Risk factors for hip fractures in white women. N Engl J Med 332:767–773CrossRefPubMedGoogle Scholar
  30. 30.
    Siris ES, Modi A, Tang J, Gandhi S, Sen S (2014) Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. Curr Med Res Opin 30:123–130CrossRefPubMedGoogle Scholar
  31. 31.
    Weaver J, Sajjan S, Lewiecki EM, Harris ST (2017) Diagnosis and treatment of osteoporosis before and after fracture: a side-by-side analysis of commercially insured and Medicare advantage osteoporosis patients. J Manage Care Specialty Pharm 23:735–744CrossRefGoogle Scholar
  32. 32.
    Siris ES, Simon JA, Barton IP, McClung MR, Grauer A (2008) Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int: J Established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA 19:681–686CrossRefGoogle Scholar
  33. 33.
    Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809CrossRefPubMedGoogle Scholar
  34. 34.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMedGoogle Scholar
  35. 35.
    Ryder KM, Cummings SR, Palermo L, Satterfield S, Bauer DC, Feldstein AC, Schousboe JT, Schwartz AV, Ensrud K (2008) Does a history of non-vertebral fracture identify women without osteoporosis for treatment? J Gen Intern Med 23:1177–1181CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Qaseem A, Forciea MA, McLean RM, Denberg TD (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166:818–839CrossRefPubMedGoogle Scholar
  37. 37.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMedGoogle Scholar
  38. 38.
    Siris ES, Boonen S, Mitchell PJ, Bilezikian J, Silverman S (2012) What’s in a name? What constitutes the clinical diagnosis of osteoporosis? Osteoporos Int: J Established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA 23:2093–2097CrossRefGoogle Scholar
  39. 39.
    Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int: J Established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA 21:495–505CrossRefGoogle Scholar
  40. 40.
    Adler RA (2014) Osteoporosis in men: a review. Bone research 2:14001CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Bultink IE, Baden M, Lems WF (2013) Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 14:185–197CrossRefPubMedGoogle Scholar
  42. 42.
    Lems WF (2007) Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 56:3518–3522CrossRefPubMedGoogle Scholar
  43. 43.
    van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. JBone MinerRes 15:993–1000CrossRefGoogle Scholar
  44. 44.
    McCloskey EV, Harvey NC, Johansson H, Kanis JA (2016) FRAX updates 2016. Curr Opin Rheumatol 28:433–441CrossRefPubMedGoogle Scholar
  45. 45.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix A, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMedGoogle Scholar
  46. 46.
    Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J (2012) The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Med Res Methodol 12:143CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023–2038CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  1. 1.Department of Public Health and NursingNTNU, Norwegian University of Science and TechnologyTrondheimNorway
  2. 2.Department of RheumatologySt. Olavs HospitalTrondheimNorway
  3. 3.Norwegian Institute of Public HealthOsloNorway
  4. 4.Norwegian Centre for Addiction ResearchUniversity of OsloOsloNorway
  5. 5.Department of Community Medicine and Global HealthUniversity of OsloOsloNorway
  6. 6.Department of EndocrinologySt. Olavs HospitalTrondheimNorway
  7. 7.Institute of Cancer Research and Molecular MedicineNTNUTrondheimNorway
  8. 8.Department of MedicineHolbæk HospitalHolbækDenmark
  9. 9.Odense Patient Data Explorative Network, Institute of Clinical ResearchUniversity of Southern DenmarkOdenseDenmark
  10. 10.Department of GynecologySt. Olavs HospitalTrondheimNorway

Personalised recommendations